The Viral Connection to Glioblastoma

Current Infectious Disease Reports

Volumn 19, Issue 2, 2017, Pages

  McFaline Figueroa, J Ricardo ^a   Wen, Patrick Y ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Glioblastoma; Herpesvirus; Immunotherapy; Valganciclovir

Indexed keywords

BEVACIZUMAB; CIDOFOVIR; DENDRITIC CELL VACCINE; PLACEBO; VALGANCICLOVIR; VIRUS DNA;

ADJUVANT CHEMORADIOTHERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SIZE; CD8+ T LYMPHOCYTE; COMPASSIONATE USE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD;

EID: 85013627817     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-017-0563-z     Document Type: Review

References (35)

1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17 Suppl 4:iv1–62.
2. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.
3. Shein HM. Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus. Science. 1968;159:1476–7.
4. Rabotti GF, Anderson WR, Sellers RL. Oncogenic activity of Mill Hill (Harris) strain of Rous sarcoma virus for hamsters. Nature. 1965;206:946–7.
5. Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. Cancer Res. 1969;29:1173–8.
6. Yung WK, Blank NK, Vick NA. “Glioblastoma”. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology. 1976;26:76–83.
7. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–50. This study first detected human cytomegalovirus DNA, RNA and proteins in human glioblastoma post-surgical samples.
8. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10:10–8.
9. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.
10. Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–43.
11. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–9.
12. Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci. 2015;22:326–30.
13. Lin C-TM, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016;11:32. BioMed Central.
14. Scheurer ME, El-Zein R, Bondy ML, Harkins L, Cobbs CS. RE: “Lack of association of herpesviruses with brain tumors”. J Neurovirol. 2007;13:85. author reply 86–7.
15. Poland SD, Costello P, Dekaban GA, Rice GP. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis. 1990;162:1252–62.
16. Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol. 1986;67(Pt 12):2605–16.
17. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia. 2009;11:1–9.
18. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204–13. This small, exploratory, double-blind, randomized control trial showed no benefit to adjuvant valganciclovir in regards to tumor progression, overall survival or progression free survival at 6 months.
19. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–6. This retrospective analysis of the VIGAS trial, as well as other, non-study patients receiving valganciclovir, suggests a survival benefit to receiving at least 6 months of adjuvant valganciclovir.
20. Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology. 2014;16:166.
21. Liu C-J, Hu Y-W. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135:250–1.
22. Söderberg-Nauclér C, Peredo I, Rahbar A, Hansson F, Nordlund A, Stragliotto G. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 2014;135:248–9.
23. Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience. Mol Clin Oncol. 2016;4:154–8.
24. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–55.
25. Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066.
26. Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066–7.
27. Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol. 2001;154:161–5.
28. Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. OncoImmunology. 2015;4:e982391.
29. Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–83.
30. Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. Springer US.
31. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359:539–41.
32. Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9. This small, double-blinded, randomized-control trial of vaccination with pp65-exposed dendritic cells (a HCMV antigen) after tetanus/diphteria toxin preconditioning showed increased progression-free survival and overall survival in glioblastoma patients.
33. Nair SK, Sampson JH, Mitchell DA. Immunological targeting of cytomegalovirus for glioblastoma therapy. OncoImmunology. 2014;3:e29289.
34. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012;90:872–80.
35. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466–76.